Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Kidney and Ureter Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Urinary System Neoplasm
Kidney and Ureter Neoplasm

Subtype

Kidney and Ureter Neoplasm

CI-CAN-00001051Explore in graph →

Non-malignant518 active trials17 approved drugs81 evidence items

NCIt: C7514

Overview
Statistics
Survival
Genomics30
Variants & evidence81
Drugs11
Trials2409
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (98)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 30, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 98 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.
Umberto Capitanio, Axel Bex, Grant D Stewart et al. · Eur Urol · Aug 14, 2026 · PMID 42601237 · candidate dictionary pubmed
The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050.
Jia Deng, Bing Yang, Zhenzhen Wu et al. · Tob Induc Dis · Jan 1, 2026 · PMID 42746221 · candidate dictionary pubmed
Integrated molecular analysis of clear-cell renal cell carcinoma.
· Nat Genet · 2013 · PMID 23797736 · validated civic_curation pubmed
Comprehensive molecular characterization of clear cell renal cell carcinoma.
· Nature · 2013 · PMID 23792563 · validated cbioportal_study pubmed
Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.
· Nat Commun · 2015 · PMID 26573325 · validated civic_curation pubmed
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.
· Int J Cancer · 2008 · PMID 18464292 · validated civic_curation

Showing 26–50 of 98 publications

← Previous
1
2
3
4
Next →

The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.

· Clin Cancer Res · 2006 · PMID 16467086 · validated civic_curation pubmed

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

· Oncotarget · 2017 · PMID 28103578 · validated civic_curation pubmed

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

· J Clin Oncol · 2016 · PMID 26951309 · validated civic_curation pubmed

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

· Eur Urol · 2017 · PMID 27751729 · validated civic_curation pubmed

Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.

· Future Oncol · 2015 · PMID 26169997 · validated civic_curation pubmed

Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney.

· Nat Genet · 2015 · PMID 26098867 · validated civic_curation pubmed

TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

· Am J Surg Pathol · 2016 · PMID 26975036 · validated civic_curation pubmed

Integrative clinical and molecular characterization of translocation renal cell carcinoma.

· Cell Rep · 2022 · PMID 34986355 · validated civic_curation pubmed

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.

· Clin Cancer Res · 2013 · PMID 23620406 · validated civic_curation pubmed

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.

· J Pathol · 2002 · PMID 11793370 · validated civic_curation pubmed

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

· Lancet Oncol · 2013 · PMID 23333114 · validated civic_curation pubmed

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

· J Clin Oncol · 2013 · PMID 23213094 · validated civic_curation pubmed

Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.

· Onco Targets Ther · 2015 · PMID 26309414 · validated civic_curation pubmed

Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.

· Oncotarget · 2016 · PMID 27092876 · validated civic_curation pubmed

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

· J Clin Oncol · 2009 · PMID 19667267 · validated civic_curation pubmed

Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.

· JAMA · 2010 · PMID 21177507 · validated civic_curation pubmed

Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma.

· Hum Pathol · 2015 · PMID 25628030 · validated civic_curation pubmed

Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor.

· Iran J Kidney Dis · 2011 · PMID 21525573 · validated civic_curation pubmed

ETV6-NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study.

· Pediatr Blood Cancer · 2018 · PMID 29286563 · validated civic_curation pubmed